MG
GPCR icon

Mather Group’s Structure Therapeutics GPCR Stock Holding History

Mather Group’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-35
Closed -$606 – 1057
2025
Q1 		$606 Buy
+35
New +$857 ﹤0.01% 1674
2024
Q3 		– Sell
-5,000
Closed -$214K – 1906
2024
Q2 		$214K Buy
+5,000
New +$205K ﹤0.01% 595

Other funds holding GPCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Mather Group's GPCR Position: Q2 2025 in Review

Mather Group sold out of Structure Therapeutics (GPCR) in Q2 2025, closing a stake of 35 shares — an estimated $606 sold.

Mather Group first reported a position in GPCR in Q2 2024 and held it in 2 quarters. The position peaked at $214K in Q2 2024. 172 funds tracked by Wall St. Rank hold GPCR as of Q2 2025.

  • Mather Group reported no remaining Structure Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Mather Group sold 35 Structure Therapeutics shares in Q2 2025, an estimated $606.
  • Mather Group first reported a position in Structure Therapeutics in Q2 2024 and held it in 2 quarters.
  • Mather Group's Structure Therapeutics position peaked at $214K in Q2 2024.
  • 172 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2025.

Based on Mather Group's 13F filing for Q2 2025, filed 15 Jul 2025.